Financial Results for the Six-Month Period Ended September 30,2026 Reference Data
Filed with TSE · · 24 pages · English
Summary by 6ix AI
The report includes consolidated statements of income, cash flows, and financial position, along with segment information for various pharmaceutical businesses. It also discusses risks and uncertainties that may impact future results, emphasizing the company's strategies to mitigate these risks. The filing serves to inform investors about the company's financial health and operational updates for the specified period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/financial-results-for-the-six-month-period-ended-september-302026-reference-data
In the deck
Earlier from Eisai
- Revenue of LEQEMBI (Preliminary Basis)
- Notification Regarding Receipt of Dividend from a Consolidated Subsidiary
- U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
- Leqembi® Pen subcutaneous formulation approved in Japan
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
Later from Eisai
All Eisai news releasesFollow Eisai into a list and get an email when it puts out news.
Follow Eisai